RxDoctor Payments Data

Andrew Chow, MD

Hospitalist · Greensboro, NCNPI 1376583245

Payments from drug & device makers

$3,473in general payments, 2019–2025

Across 194 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$906
  • AstraZeneca$586
  • AbbVie$374
  • Lilly USA, LLC$301
  • Novo Nordisk$224
  • Bayer$121
  • plus $962 from 29 others

What the payments were for

  • Food & beverage$3,473100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,473 in reported general payments places this provider in the 85th percentile of 879 hospitalist providers in North Carolina.

See all hospitalist providers in North Carolina

Medicare billing

Part B allowed, 2024
$80,358
Medicare patients
167
Services billed
937

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban75$96,011
JardianceEmpagliflozin45$66,276
FarxigaDapagliflozin Propanediol43$58,484
XareltoRivaroxaban41$42,107
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$27,380
JanuviaSitagliptin Phosphate15$24,178
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl78$10,522
SymbicortBudesonide/Formoterol Fumarate20$6,834
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$5,024
Atorvastatin Calcium513$3,618
Gabapentin116$3,401
Amlodipine Besylate497$3,171
Albuterol Sulfate HfaAlbuterol Sulfate79$2,964
Rosuvastatin Calcium320$2,887
Levothyroxine Sodium323$2,607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$906$96,01175 claims
Boehringer IngelheimJardiance$98$66,27645 claims
AstraZenecaFarxiga, Symbicort$586$65,31863 claims
GSKTrelegy Ellipta$90$27,38031 claims
MerckJanuvia$47$24,17815 claims
AbbVieSynthroid$374$1,50716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 879 hospitalist providers in North Carolina.

Other hospitalist in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →